Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities (2024 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Total Non-Current Liabilities of $45.7 million for Q1 2026, down 5.1% quarter-over-quarter from $48.2 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Total Non-Current Liabilities for 3 consecutive years, with $45.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $45.7 million; the TTM figure through Mar 2026 stood at $45.7 million (changed N/A YoY), while the FY2025 annual figure was $48.2 million, up 11.49% from the prior year.
- Total Non-Current Liabilities declined to $45.7 million in Q1 2026 per XENE's latest filing, from $48.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $48.2 million in Q4 2025 and bottomed at $43.2 million in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $45.6 million across 3 years, with a median of $45.5 million in 2025.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 11.49% in 2025 and fell as far as 11.49% in 2025.
- Xenon Pharmaceuticals' Total Non-Current Liabilities stood at $43.2 million in 2024, then rose by 11.49% to $48.2 million in 2025, then retreated by 5.1% to $45.7 million in 2026.
- Business Quant data shows XENE's Total Non-Current Liabilities at $45.7 million in Q1 2026, $48.2 million in Q4 2025, and $45.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 50.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.09 Mn |
| Mar 31, 2026 | 45.75 Mn |
| Dec 31, 2025 | 48.20 Mn |
| Sep 30, 2025 | 45.17 Mn |
| Dec 31, 2024 | 43.24 Mn |